- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
Podcast- End of the world as we know it?
REMS: Is it the end of the world as we know it?
Risk Evaluation and Mitigation Strategies: For manufacturers, do REMS represent a tremendous potential for confusion or an opportunity for growth? Perhaps both. Manufacturers who implement effective programs can enhance patient access to medications, further ensure appropriate utilization and potentially improve patient outcomes. Manufacturers whose execution falls short stand to lose market share or even risk increased regulatory scrutiny.
Add this Podcast feed to your media player
Click Here To Listen to More of the ABSG Podcast Series
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
Fake Weight Loss Drugs: Growing Threat to Consumer Health
October 25th 2024In this episode of the Pharmaceutical Executive podcast, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, discuss the issue of counterfeit weight loss drugs, the potential health risks associated with them, increasing access to legitimate weight loss medications and more.
